Association Between Plasma Concentration of Klotho Protein, Osteocalcin, Leptin, Adiponectin, and Bone Mineral Density in Patients with Chronic Kidney Disease

Abstract

Patients with early-stage chronic kidney disease (CKD) are susceptible to changes in metabolic processes. Partial loss of kidney function leads to homoeostatic disturbances in bone and fatty tissue. The aim of this study was to investigate the association between plasma concentrations of Klotho protein, FGF23, leptin, adiponectin, osteocalcin, and bone mineral density (BMD) in patients with CKD in the pre-dialysis period. The study involved 52 patients with CKD and 23 patients with no kidney disease. In both groups, BMD, body mass index and serum or plasma concentrations of lipids, glucose, creatinine, calcium, phosphorus, parathormone, leptin, adiponectin, osteocalcin, Klotho, and FGF23 were measured. The group with CKD had statistically significant higher concentrations of leptin (p<0.001), parathormone (p<0.001), and osteocalcin (p<0.001) in comparison with the control group. Patients with CKD also had statistically significant lower BMD in the femoral neck in comparison with the control group. Osteocalcin correlated negatively with BMD. The results of our study suggest that elevated osteocalcin is the most sensitive marker of decreased bone mass in patients with CKD. Osteocalcin correlated negatively with BMD and GFR. The loss of bone mass in CKD patients was greatest in the femoral neck.

Key words

Klotho protein - osteocalcin - leptin - adiponectin - bone mineral density - chronic kidney disease

• References

• 1 Magni P, Dozio E, Galliera E, Ruscica M, Corsi MM. Molecular aspects of adipokine-bone interactions. Curr Mol Med 2010; 10: 522-532
• 2 Cappariello A, Ponzetti M, Rucci N. The “soft” side of the bone: Unveiling its endocrine functions. Horm Mol Biol Clin Investig 2016; 28: 5-20
• 3 Pedone C, Roshanravan B, Scarlata S, Patel KV, Ferrucci L, Incalzi RA. Longitudinal association between serum leptin concentration and glomerular filtration rate in humans. PLoS One 2015; 10: e0117828
• 4 Tesauro M, Mascali A, Franzese O, Cipriani S, Cardillo C, Di Daniele N. Chronic kidney disease, obesity, and hypertension: The role of leptin and adiponectin. Int J Hypertens 2012; 2012: 943605
• 5 Arita Y, Kihara S, Ouchi N, Takahashi M, Maeda K, Miyagawa J, Hotta K, Shimomura I, Nakamura T, Miyaoka K, Kuriyama H, Nishida M, Yamashita S, Okubo K, Matsubara K, Muraguchi M, Ohmoto Y, Funahashi T, Matsuzawa Y. Paradoxical decrease of an adipose-specific protein, adiponectin, in obesity. Biochem Biophys Res Commun 1999; 257: 79-83
• 6 Kadowaki T, Yamauchi T, Okada-Iwabu M, Iwabu M. Adiponectin and its receptors: Implications for obesity-associated diseases and longevity. Lancet Diabetes Endocrinol 2014; 2: 8-9
• 7 Zoccali C, Mallamaci F, Tripepi G, Benedetto FA, Cutrupi S, Parlongo S, Malatino LS, Bonanno G, Seminara G, Rapisarda F, Fatuzzo P, Buemi M, Nicocia G, Tanaka S, Ouchi N, Kihara S, Funahashi T, Matsuzawa Y. Adiponectin, metabolic risk factors, and cardiovascular events among patients with end-stage renal disease. J Am Soc Nephrol 2002; 13: 134-141
• 8 Guebre-Egziabher F, Bernhard J, Funahashi T, Hadj-Aissa A, Fouque D. Adiponectin in chronic kidney disease is related more to metabolic disturbances than to decline in renal function. Nephrol Dial Transplant 2005; 20: 129-134
• 9 Pi M, Quarles LD. Novel bone endocrine networks integrating mineral and energy metabolism. Curr Osteoporos Rep 2013; 11: 391-399
• 10 Thomas T, Gori F, Khosla S, Jensen MD, Burguera B, Riggs BL. Leptin acts on human marrow stromal cells to enhance differentiation to osteoblasts and to inhibit differentiation to adipocytes. Endocrinology 1999; 140: 1630-1638
• 11 Chenu C, Colucci S, Grano M, Zigrino P, Barattolo R, Zambonin G, Baldini N, Vergnaud P, Delmas PD, Zallone AZ. Osteocalcin induces chemotaxis, secretion of matrix proteins, and calcium-mediated intracellular signaling in human osteoclast-like cells. J Cell Biol 1994; 127: 1149-1158
• 12 Wang Y, Sun Z. Current understanding of klotho. Ageing Res Rev 2009; 8: 43-51
• 13 Tsuchiya K, Nagano N, Nitta K. Klotho/FGF23 Axis in CKD. Contrib Nephrol 2015; 185: 56-65
• 14 Chihara Y, Rakugi H, Ishikawa K, Ikushima M, Maekawa Y, Ohta J, Kida I, Ogihara T. Klotho protein promotes adipocyte differentiation. Endocrinology 2006; 147: 3835-3842
• 15 Wang Y, Sun Z. Klotho gene delivery prevents the progression of spontaneous hypertension and renal damage. Hypertension 2009; 54: 810-817
• 16 Ohnishi M, Kato S, Akiyoshi J, Atfi A, Razzaque MS. Dietary and genetic evidence for enhancing glucose metabolism and reducing obesity by inhibiting klotho functions. FASEB J 2011; 25: 2031-2039
• 17 Tseng T, Mu C, Hsu C. The correlation between renal function and bone mineral density. Minerva Urol Nefrol 2014; 66: 153-156
• 18 Quarles LD. A systems biology preview of the relationships between mineral and metabolic complications in chronic kidney disease. Semin Nephrol 2013; 33: 130-142
• 19 Kanazawa I. Adiponectin in metabolic bone disease. Curr Med Chem 2012; 19: 5481-5492
• 20 Nickolas TL, Cremers S, Zhang A, Thomas V, Stein E, Cohen A, Chauncey R, Nikkel L, Yin MT, Liu XS, Boutroy S, Staron RB, Leonard MB, McMahon DJ, Dworakowski E, Shane E. Discriminants of prevalent fractures in chronic kidney disease. J Am Soc Nephrol 2011; 22: 1560-1572
• 21 Larsson T, Nisbeth U, Ljunggren O, Jüppner H, Jonsson KB. Circulating concentration of FGF-23 increases as renal function declines in patients with chronic kidney disease, but does not change in response to variation in phosphate intake in healthy volunteers. Kidney Int 2003; 64: 2272-2279
• 22 Hamann A, Matthaei S. Regulation of energy balance by leptin. Exp Clin Endocrinol Diabetes 1996; 104: 293-300
• 23 Burguera B, Hofbauer LC, Thomas T, Gori F, Evans GL, Khosla S, Riggs BL, Turner RT. Leptin reduces ovariectomy-induced bone loss in rats. Endocrinology 2001; 142: 3546-3553
• 24 Takeda S, Elefteriou F, Levasseur R, Liu X, Zhao L, Parker KL, Armstrong D, Ducy P, Karsenty G. Leptin regulates bone formation via the sympathetic nervous system. Cell 2002; 111: 305-317
• 25 Mallamaci F, Tripepi G, Zoccali C. Leptin in end stage renal disease (ESRD): A link between fat mass, bone and the cardiovascular system. J Nephrol 2005; 18: 464-468
• 26 Tsuji K, Maeda T, Kawane T, Matsunuma A, Horiuchi N. Leptin stimulates fibroblast growth factor 23 expression in bone and suppresses renal 1alpha,25-dihydroxyvitamin D3 synthesis in leptin-deficient mice. J Bone Miner Res 2010; 25: 1711-1723
• 27 Ghazali A, Grados F, Oprisiu R, Bunea D, Morinière P, Esper NE, Esper IE, Brazier M, Souberbielle JC, Fournier A, Thomas T. Bone mineral density directly correlates with elevated serum leptin in haemodialysis patients. Dial Transplant 2003; 9: 1882-1890
• 28 Ghonemy TA, Salim EM, Atia M, Fekry A, Shawky K. Serum leptin and bone mineral density in hemodialysis patients with or without liver diseases. Arab J Nephrol Transplant 2011; 4: 131-136
• 29 Hum JM, O'Bryan L, Smith RC, White KE. Novel functions of circulating Klotho. Bone 2017; 100: 36-40
• 30 Mirza MA, Alsiö J, Hammarstedt A, Erben RG, Michaëlsson K, Tivesten A, Marsell R, Orwoll E, Karlsson MK, Ljunggren O, Mellström D, Lind L, Ohlsson C, Larsson TE. Circulating fibroblast growth factor-23 is associated with fat mass and dyslipidemia in two independent cohorts of elderly individuals. Arterioscler Thromb Vasc Biol 2011; 31: 219-227
• 31 Chalhoub D, Marques E, Meirelles O, Semba RD, Ferrucci L, Satterfield S, Nevitt M, Cauley JA, Harris T. Health ABC Study. Association of serum klotho with loss of bone mineral density and fracture risk in older adults. J Am Geriatr Soc 2016; 64: e304-e308
• 32 Yaghoubi F, Ahmadi F, Lesanpezeshki M, Mahdavi Mazde M. A study on the association of serum fibroblast growth factor-23 with various indices of chronic kidney disease patients not yet on dialysis. J Renal Inj Prev 2016; 5: 104-107
• 33 Menon V, Li L, Wang X, Greene T, Balakrishnan V, Madero M, Pereira AA, Beck GJ, Kusek JW, Collins AJ, Levey AS, Sarnak MJ. Adiponectin and mortality in patients with chronic kidney disease. J Am Soc Nephrol 2006; 17: 2599-2606
• 34 Norata GD, Baragetti I, Raselli S, Stucchi A, Garlaschelli K, Vettoretti S, Piloni G, Buccianti G, Catapano AL. Plasma adiponectin levels in chronic kidney disease patients: Relation with molecular inflammatory profile and metabolic status. Nutr Metab Cardiovasc Dis 2010; 20: 56-63
• 35 Bacchetta J, Boutroy S, Guebre-Egziabher F, Juillard L, Drai J, Pelletier S, Richard M, Charrié A, Carlier MC, Chapurlat R, Laville M, Fouque D. The relationship between adipokines, osteocalcin and bone quality in chronic kidney disease. Nephrol Dial Transplant 2009; 24: 3120-3125
• 36 Okuno S, Ishimura E, Norimine K, Tsuboniwa N, Kagitani S, Yamakawa K, Yamakawa T, Sato KK, Hayashi T, Shoji S, Nishizawa Y, Inaba M. Serum adiponectin and bone mineral density in male hemodialysis patients. Osteoporos Int 2012; 23: 2027-2035
• 37 Wang QP, Li XP, Wang M, Zhao LL, Li H, Xie H, Lu ZY. Adiponectin exerts its negative effect on bone metabolism via OPG/RANKL pathway: An in vivo study. Endocrine 2014; 47: 845-853
• 38 Chen T, Wu YW, Lu H, Guo Y, Tang ZH. Adiponectin enhances osteogenic differentiation in human adipose-derived stem cells by activating the APPL1-AMPK signaling pathway. Biochem Biophys Res Commun 2015; 461: 237-242